Spruce Biosciences Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Public

  • Employees
  • 8

Employees

  • Stock Symbol
  • SPRB

Stock Symbol

  • Share Price
  • $38.02
  • (As of Friday Closing)

Spruce Biosciences General Information

Description

Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company develops biologics and small-molecule product candidates aimed at addressing diseases with unmet medical needs and limited or no approved therapies. Its product candidate, TA-ERT for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) intended as an enzyme replacement therapy for patients who lack rhNAGLU enzyme activity. TA-ERT is designed to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection and promote clearance of heparan sulfate in the brain.

Contact Information

Website
sprucebio.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 611 Gateway Boulevard
  • Suite 740
  • South San Francisco, CA 94080
  • United States
+1 (415)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 611 Gateway Boulevard
  • Suite 740
  • South San Francisco, CA 94080
  • United States
+1 (415)

Spruce Biosciences Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Spruce Biosciences Stock Performance

As of 20-Nov-2026, Spruce Biosciences’s stock price is $38.02. Its current market cap is $109M with 2.87M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$38.02 $40.81 $38.01 - $112.26 $109M 2.87M 89.3K -$33.29

Spruce Biosciences Financials Summary

As of 30-Sep-2026, Spruce Biosciences has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 50,997 83,919 (39,478) 16,312
Revenue 0 0 4,911 10,089
EBITDA (65,090) (39,992) (56,105) (51,923)
Net Income (67,147) (38,966) (53,036) (47,919)
Total Assets 91,948 53,021 45,209 103,946
Total Debt 8,322 736 2,765 4,609
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Spruce Biosciences Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Spruce Biosciences‘s full profile, request access.

Request a free trial

Spruce Biosciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Spruce Biosciences‘s full profile, request access.

Request a free trial

Spruce Biosciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapi
Biotechnology
South San Francisco, CA
8 As of 2025

Calimera, Italy
 

San Diego, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Spruce Biosciences Competitors (2)

One of Spruce Biosciences’s 2 competitors is Gelesis, a Formerly VC-backed company based in Calimera, Italy.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Gelesis Formerly VC-backed Calimera, Italy
Crinetics Pharmaceuticals Formerly VC-backed San Diego, CA
You’re viewing 2 of 2 competitors. Get the full list »

Spruce Biosciences Patents

Spruce Biosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025188842-A1 Amorphous solid dispersion of tildacerfont formulations Pending 08-Mar-2024
WO-2025188842-A8 Amorphous solid dispersion of tildacerfont formulations Pending 08-Mar-2024
WO-2025038392-A1 Methods and compositions for treating polycystic ovary syndrome Inactive 11-Aug-2023
WO-2024243431-A1 Tildacerfont cocrystal formulations Inactive 24-May-2023
CA-3235958-A1 Crystalline composition of tildacerfont and methods of use and preparation thereof Pending 19-Nov-2021 A61K31/5377
To view Spruce Biosciences’s complete patent history, request access »

Spruce Biosciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Spruce Biosciences Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Spruce Biosciences‘s full profile, request access.

Request a free trial

Spruce Biosciences ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

37.21 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Spruce Biosciences’s complete esg history, request access »

Spruce Biosciences FAQs

  • When was Spruce Biosciences founded?

    Spruce Biosciences was founded in 2016.

  • Where is Spruce Biosciences headquartered?

    Spruce Biosciences is headquartered in South San Francisco, CA.

  • What is the size of Spruce Biosciences?

    Spruce Biosciences has 8 total employees.

  • What industry is Spruce Biosciences in?

    Spruce Biosciences’s primary industry is Biotechnology.

  • Is Spruce Biosciences a private or public company?

    Spruce Biosciences is a Public company.

  • What is Spruce Biosciences’s stock symbol?

    The ticker symbol for Spruce Biosciences is SPRB.

  • What is the current stock price of Spruce Biosciences?

    As of 20-Nov-2026 the stock price of Spruce Biosciences is $38.02.

  • What is the current market cap of Spruce Biosciences?

    The current market capitalization of Spruce Biosciences is $109M.

  • Who are Spruce Biosciences’s competitors?

    Gelesis and Crinetics Pharmaceuticals are competitors of Spruce Biosciences.

  • What is Spruce Biosciences’s annual earnings per share (EPS)?

    Spruce Biosciences’s EPS for 12 months was -$33.29.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process